<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04690803</url>
  </required_header>
  <id_info>
    <org_study_id>ScleroTT2019-01</org_study_id>
    <nct_id>NCT04690803</nct_id>
  </id_info>
  <brief_title>The Effect of Cooling on Sclerotherapy Efficacy</brief_title>
  <official_title>The Effect of Cooling on Sclerotherapy Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Goldman, Butterwick, Fitzpatrick and Groff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Goldman, Butterwick, Fitzpatrick and Groff</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of sclerotherapy with&#xD;
      forced-air cooling during treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Objective: The primary objective of this study is to evaluate the efficacy of&#xD;
      sclerotherapy with forced-air cooling during treatment.&#xD;
&#xD;
      Study Design: This will be an investigator-initiated, evaluator-blinded,&#xD;
      randomized-controlled, prospective, single-center clinical trial.&#xD;
&#xD;
      Study Population: 20 evaluable subjects with bilateral lower extremity reticular and&#xD;
      telangiectatic veins, who meet all study inclusion/exclusion criteria will be considered for&#xD;
      entry into the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 6, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>sclerotherapy with forced-air cooling during treatment.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>evaluator-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>to evaluate the effect of forced-air cooling on sclerotherapy</measure>
    <time_frame>1 year</time_frame>
    <description>to evaluate the effect of forced-air cooling on sclerotherapy of lower extremity telangiectasias and reticular veins. This will be assessed by comparing treatment with and without forced-air cooling in a comparative lower extremity model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>is to compare reticular vein and telangiectasia diameter measurements</measure>
    <time_frame>1 year</time_frame>
    <description>to compare reticular vein and telangiectasia diameter measurements via a polarized LED wireless digital microscope before treatment and during cooling in the forced-air cooling group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Leg Veins</condition>
  <arm_group>
    <arm_group_label>treatment with forced-air cooling</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparing treatment with and without forced-air cooling in a comparative lower extremity model</description>
  </arm_group>
  <arm_group>
    <arm_group_label>treatment without forced-air cooling</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>comparing treatment without forced-air cooling in a comparative lower extremity model</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>air cooling</intervention_name>
    <description>intervention is adding air-cooling to treatment</description>
    <arm_group_label>treatment with forced-air cooling</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject is a male or female of skin type I to IV between 25 and 75 years of age.&#xD;
&#xD;
          -  The subject has mild venous disease (CEAP Class C1) (CLINICAL SEVERITY ETIOLOGY OR&#xD;
             CAUSE ANATOMY AND PATHOPHYSIOLOGY)&#xD;
&#xD;
          -  Reticular veins and telangiectasias on symmetrical bilateral lower extremities.&#xD;
&#xD;
          -  The subject is willing to follow study instructions and complete all required visits,&#xD;
             as well as has agreed to and signed the written informed consent form.&#xD;
&#xD;
          -  The subject is healthy as judged by medical history and investigator's assessment of&#xD;
             current health.&#xD;
&#xD;
          -  The subject is not suffering from any skin condition (infection, dermatosis, etc.)&#xD;
             that in the opinion of the investigator may place them at risk.&#xD;
&#xD;
          -  Females of childbearing potential must use one of the following types of birth control&#xD;
             for the duration of the study. These include: Oral contraceptives, contraceptive&#xD;
             patches/rings/implants, Implanon®, Depo-Provera®, double-barrier methods (e.g. condoms&#xD;
             with spermicide), abstinence, or partner vasectomy, with a documented second&#xD;
             acceptable method of birth control should they become sexually active. All birth&#xD;
             control measures must be in consistent use for at least 30 days prior to the start of&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject requires greater than 10 mL total of glycerin, including a maximum of 6 mL&#xD;
             of polidocanol for foam sclerotherapy, for either lower extremity during a single leg&#xD;
             treatment.&#xD;
&#xD;
          -  Asymmetric amount, distribution, and/or severity of reticular veins and/or&#xD;
             telangiectasias between lower extremities&#xD;
&#xD;
          -  The subject has a CEAP Class of C2 or greater, as evidenced by clinically apparent&#xD;
             varicosities, venous stasis, stasis dermatitis, lipodermatosclerosis, and/or venous&#xD;
             ulceration (or history of lower leg ulcerations).&#xD;
&#xD;
          -  The subject has history of or current great saphenous vein (GSV), saphenofemoral&#xD;
             junction (SFJ), or saphenopopliteal junction (SPJ) incompetency based on prior Doppler&#xD;
             and/or duplex evaluation or has physical exam findings suspicious for it.&#xD;
&#xD;
          -  The subject has a history of deep vein thrombosis, thrombophlebitis, thromboembolic&#xD;
             disease, and/or underlying hypercoagulable medical condition (e.g. hemophilia, Factor&#xD;
             V deficiency).&#xD;
&#xD;
          -  The subject has a history of uncontrolled or severe asthma, or asthma requiring&#xD;
             hospitalization or intubation.&#xD;
&#xD;
          -  The subject has a history of allergic reactions to sclerosing agent.&#xD;
&#xD;
          -  The subject has a history of allergic reaction or sensitivity to lidocaine or&#xD;
             epinephrine.&#xD;
&#xD;
          -  Any of the following medications, procedures or treatments to the purposed treatment&#xD;
             area/s&#xD;
&#xD;
               1. Within 6 months prior to screening visit (i.) The subject has undergone&#xD;
                  sclerotherapy&#xD;
&#xD;
               2. Within 3 months prior to screening visit (I.) NO OTHER COSMETIC OR SURGICAL&#xD;
                  TREATMENTS TO THE PURPOSED TREATMENT AREA/S&#xD;
&#xD;
          -  The subject is non-ambulatory or poorly ambulatory.&#xD;
&#xD;
          -  The subject has a history of neurological conditions.&#xD;
&#xD;
          -  The subject is pregnant, lactating, or in child bearing age (and sexually active) and&#xD;
             not using an approved contraceptive measure.&#xD;
&#xD;
          -  The subject is taking disulfiram, tamoxifen, or oral hormone therapy (not including&#xD;
             hormonal birth control).&#xD;
&#xD;
          -  The subject has a history of noncompliance with clinical protocols.&#xD;
&#xD;
          -  The subject has participated in any other clinical trial that involves an&#xD;
             investigational medication or device within the last 30 days.&#xD;
&#xD;
          -  Planning to have any treatments or procedures to bilateral lower extremities for the&#xD;
             duration of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Leslie Aguilar, BA</last_name>
    <phone>18586571004</phone>
    <email>laguilar@clderm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sherif Mikhail</last_name>
    <phone>8586571004</phone>
    <email>SMikhail@clderm.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Dermatology Research Center/Cosmetic Laser Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Aguilar, BA</last_name>
      <phone>858-657-1004</phone>
      <email>laguilar@clderm.com</email>
    </contact>
    <contact_backup>
      <last_name>Sherif Mikhail, MD</last_name>
      <phone>8586571004</phone>
      <email>SMikhail@clderm.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchel P Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 31, 2020</study_first_posted>
  <last_update_submitted>December 30, 2020</last_update_submitted>
  <last_update_submitted_qc>December 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

